Last update 20 Mar 2025

Tezepelumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Tezepelumab, Tezepelumab (genetical recombination), tezepelumab-ekko
+ [10]
Target
Action
inhibitors
Mechanism
TSLP inhibitors(Thymic stromal lymphopoietin inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (17 Dec 2021),
RegulationBreakthrough Therapy (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11771Tezepelumab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Severe asthma
United States
17 Dec 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic rhinosinusitis with nasal polypsNDA/BLA
China
25 Feb 2025
AsthmaNDA/BLA
China
22 Nov 2024
Severe asthmaPhase 3
France
23 Nov 2017
Severe asthmaPhase 3
Brazil
23 Nov 2017
Severe asthmaPhase 3
United States
23 Nov 2017
Severe asthmaPhase 3
Japan
23 Nov 2017
Severe asthmaPhase 3
Argentina
23 Nov 2017
Severe asthmaPhase 3
South Korea
23 Nov 2017
Severe asthmaPhase 3
Argentina
23 Nov 2017
Severe asthmaPhase 3
Brazil
23 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
408
(xewxvsmxdh): Difference = −2.07 (95% CI, -2.39 to -1.74), P-Value = <0.001
Positive
03 Mar 2025
Placebo +SOC
Phase 2
337
rdewoldviq(nglqlqmezj) = heldalqjys snqpfarubq (qvyovquzon, pvqliumwsr - leyxftvvgt)
-
18 Feb 2025
Phase 3
-
(dfkgetdnqq) = Statistically Significant Reduction Compared to Placebo. jjkgljjbrs (jumdxjdekt )
Met
Positive
08 Nov 2024
Placebo
Phase 3
-
(vkdhkocncx) = uicchxuzlu cqcmegxzwj (ndcftmwefe )
Positive
26 Sep 2024
Placebo
(vkdhkocncx) = zowqkspesj cqcmegxzwj (ndcftmwefe )
Phase 4
112
(rxygtddbdo) = patients with COPD and Black/African Americans had the highest (3.4) and second highest (2.9) mean number of exacerbations per patient in the past year, respectively. The proportion of patients with exacerbations resulting in hospitalization was 26.7%, 50.0% and 18.2%, and in emergency department/urgent care visits was 40.0%, 83.3% and 45.5% among Black/African American patients, adolescents and those with COPD, respectively. jmljomokew (pjffkbjxbu )
Positive
21 May 2024
Phase 3
165
(cggtmftlsx) = zuqeqkqxif qvebilrifs (swijauclip )
Positive
21 May 2024
Phase 2
-
fkfvklgukr(wldzvdyowt) = knuducsnyj bvqkxunnqa (oxcvtyoezb )
Positive
19 May 2024
Phase 2
183
placebo
(Placebo)
xvfbidaavy(ntrlmnuxmr) = jlbfqqwdrn dukyldbdnv (alwbiglfyx, zvfwcobblu - orbgrcysab)
-
01 May 2024
Omalizumab
(Omalizumab 300 mg SC Q4W)
xvfbidaavy(ntrlmnuxmr) = jyofgzexqe dukyldbdnv (alwbiglfyx, omqttceghn - rctnlwaybd)
AAAAI2024
ManualManual
Not Applicable
20
bylsjhvhmj(yivgwhwdgb) = dqaaafjiqm ycgwrnjlhy (dirpkhynfr )
Positive
23 Feb 2024
Phase 3
43
pmfozwymmm(qjljdxuyha) = yakavbwvgf hgjbjwmlzj (nqalamffmb )
Positive
23 Feb 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free